SUBSCRIBE
SUBSCRIBE
News   Policy

FDA Delays Decision On AstraZeneca PLC’s Motavizumab To August 27th

June 25, 2010 | 
1 min read
LONDON, June 25 (Reuters) - U.S. regulators have deferred a decision on AstraZeneca's (AZN.L) experimental infant lung drug motavizumab for two months, after outside advisers recommended against its approval in a panel review on June 2.
Regulatory
AstraZeneca Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Pointing up with fingers number three. Close up, isolated on white background.
Cancer
Replimune gets early August decision date for twice-rejected melanoma drug
June 26, 2026
 · 
3 min read
 · 
Tristan Manalac
Plan to buying new house or renovation, mortgage loan or housing expense, property maintenance or real estate insurance concept, smart businessman put jigsaw to complete or finishing house puzzle.
FDA
BIO 2026: FDA’s IND initiative is a step toward normalization after slipshod year
June 25, 2026
 · 
3 min read
 · 
Jef Akst
Insights
The Golden Triangle and the gaps: Rethinking UK biotech
June 25, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Success to win in business competition, overcome obstacles or motivation to solve problem and lead company achievement concept, confident businessman leader jump high over 3 hurdles to be winner.
Approvals
Ionis secures market expansion for Tryngolza as FDA clears severe hypertriglyceridemia use
June 25, 2026
 · 
2 min read
 · 
Tristan Manalac